Key result
Vitamin D supplementation lowers TNF-α in heart failure patients without altering other inflammatory markers.
Meta-Analysis (n=1,012)
Answers are grounded in this paper and cite their sources.
Vitamin D is reported to have anti-inflammatory properties; however the effects of vitamin D supplementation on inflammation in patients with heart failure (HF) have not been established. We performed a systematic review and meta-analysis examining effects of vitamin D supplementation on inflammatory markers in patients with HF. MEDLINE, CINAHL, EMBASE, All EBM, and Clinical Trials registries were systematically searched for RCTs from inception to 25 January 2017. Two independent reviewers screened all full text articles (no date or language limits) for RCTs reporting effects of vitamin D supplementation (any form, route, duration, and co-supplementation) compared with placebo or usual care on inflammatory markers in patients with heart failure. Two reviewers assessed risk of bias and quality using the grading of recommendations, assessment, development, and evaluation approach. Seven studies met inclusion criteria and six had data available for pooling (n = 1012). In meta-analyses, vitamin D-supplemented groups had lower concentrations of tumor necrosis factor-alpha (TNF-α) at follow-up compared with controls (n = 380; p = 0.04). There were no differences in C-reactive protein (n = 231), interleukin (IL)-10 (n = 247) or IL-6 (n = 154) between vitamin D and control groups (all p > 0.05). Our findings suggest that vitamin D supplementation may have specific, but modest effects on inflammatory markers in HF.
No takes yet. Share an insight, caveat, or question.
Rodríguez et al. (2018) conducted a meta-analysis in Heart failure (n=1,012). Vitamin D supplementation vs. Placebo or usual care was evaluated on Inflammatory markers: tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), interleukin (IL)-10, and IL-6 (p=0.04). Vitamin D supplementation significantly lowered TNF-α concentrations compared with controls in patients with heart failure (n=380; p=0.04), without affecting CRP, IL-10, or IL-6 (all p>0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: